{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:08:44Z","timestamp":1783807724853,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a national priority with far-reaching implications for patients, families, clinicians, researchers, and policymakers. Yet the term AD refers to multiple distinct meanings that are often overlooked or ambiguously applied, risking misaligned research and policy priorities that affect patient outcomes. Recent FDA approvals of passive immunotherapies and related biomarker developments show that differing interpretations of AD complicate research, regulatory decisions, payer coverage, and clinical use. In contrast to efforts aimed at revising AD nomenclature, this paper clarifies five key meanings of AD as currently used. It provides a practical framework to indicate how the term AD is applied in different ways within and across clinical, research, regulatory, and policy contexts. Each key meaning\u2014clinical (symptom-focused), genetically determined (mutation-driven), pathological (autopsy-confirmed), plaque-defined (amyloid-beta\u2013plaque-positive), and broad (can encompass multiple dementia types)\u2014may apply alone or in combination depending on context. These distinctions also raise ethical considerations, particularly for biomarker-based diagnoses and their impact on patient communication and decision-making. Using this framework helps decision-makers identify the intended AD meaning and align research, policy, and care for better patient outcomes.<\/jats:p>","DOI":"10.1007\/s11357-026-02131-z","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T02:54:19Z","timestamp":1770605659000},"page":"3263-3269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The many meanings of Alzheimer\u2019s disease and why they matter for policy, research, and care"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-9240","authenticated-orcid":false,"given":"Roderick A.","family":"Corriveau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"22","key":"2131_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1212\/WNL.0000000000007583","volume":"92","author":"DS Knopman","year":"2019","unstructured":"Knopman DS, Petersen RC, Jack CR Jr. A brief history of \u201cAlzheimer disease\u201d: multiple meanings separated by a common name. Neurology. 2019;92(22):1053\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000007583.","journal-title":"Neurology"},{"key":"2131_CR2","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. Preventing and treating dementia: research priorities to accelerate progress. Washington, DC: The National Academies Press; 2025. https:\/\/doi.org\/10.17226\/28588.","DOI":"10.17226\/28588"},{"issue":"11","key":"2131_CR3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, et al. Alzheimer disease as a clinical biological construct: an International Working Group recommendation. JAMA Neurol. 2024;81(11):1304\u201311. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3770.","journal-title":"JAMA Neurol"},{"issue":"2","key":"2131_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171\u201386. https:\/\/doi.org\/10.1007\/s00401-017-1717-7.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2131_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","volume":"19","author":"R Duara","year":"2022","unstructured":"Duara R, Barker W. Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: implications for therapeutic trials. Neurotherapeutics. 2022;19(2):8\u201325. https:\/\/doi.org\/10.1007\/s13311-022-01185-z.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"2131_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jamaneurol.2019.1667","volume":"76","author":"T Gomez-Isla","year":"2019","unstructured":"Gomez-Isla T, Frosch MP. The challenge of defining Alzheimer disease based on biomarkers in the absence of symptoms. JAMA Neurol. 2019;76(10):1143\u20134. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1667.","journal-title":"JAMA Neurol"},{"key":"2131_CR7","unstructured":"U.S. Food and Drug Administration. Prescribing information: Aduhelm (aducanumab-avwa). 2023.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761178s011lbl.pdf. Accessed December 17, 2025."},{"key":"2131_CR8","unstructured":"U.S. House of Representatives, Committees on Oversight and Reform and Energy and Commerce. The high price of Aduhelm\u2019s approval: an investigation into FDA\u2019s atypical review process and Biogen\u2019s aggressive launch plans. Washington, DC: US House of Representatives; December 29, 2022. https:\/\/71b09ab5-92f6-46df-b19c-4d6ee5751c95.filesusr.com\/ugd\/8c1d0a_cac9b89db948442e9eda9e16708beecb.pdf. Accessed November 1, 2025."},{"issue":"17","key":"2131_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"GC Alexander","year":"2021","unstructured":"Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717\u20138. https:\/\/doi.org\/10.1001\/jama.2021.3854.","journal-title":"JAMA"},{"key":"2131_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12944","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS, et al. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023. https:\/\/doi.org\/10.1111\/psyg.12944.","journal-title":"Psychogeriatrics"},{"key":"2131_CR11","unstructured":"Biogen to shut down controversial Alzheimer\u2019s drug Aduhelm. AP News. January 31, 2024. https:\/\/apnews.com\/article\/biogen-alzheimer-aduhelm-dfb364a61e4e77da27fc055e826b9a49. Accessed December 17, 2025."},{"key":"2131_CR12","unstructured":"U.S. Food and Drug Administration. Prescribing information: LEQEMBI (lecanemab-irmb) injection for intravenous use. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761269s013lbl.pdf. Accessed December 17, 2025."},{"key":"2131_CR13","unstructured":"U.S. Food and Drug Administration. Prescribing information: KISUNLA (donanemab-azbt) injection for intravenous use. 2025.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761248s004lbl.pdf\n. Accessed December 17, 2025."},{"issue":"4","key":"2131_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s44319-024-00294-4","volume":"25","author":"P Hunter","year":"2024","unstructured":"Hunter P. The controversy around anti-amyloid antibodies for treating Alzheimer\u2019s disease. EMBO Rep. 2024;25(4):e57428. https:\/\/doi.org\/10.1038\/s44319-024-00294-4.","journal-title":"EMBO Rep"},{"issue":"3","key":"2131_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1474-4422(24)00041-3","volume":"23","author":"The Lancet Neurology","year":"2024","unstructured":"The Lancet Neurology. Dementia diagnosis in the anti-amyloid era. Lancet Neurol. 2024;23(3):219. https:\/\/doi.org\/10.1016\/S1474-4422(24)00041-3.","journal-title":"Lancet Neurol"},{"key":"2131_CR16","unstructured":"Centers for Medicare & Medicaid Services. Decision memo for monoclonal antibodies directed against amyloid for the treatment of Alzheimer\u2019s disease (CAG-00460N). Baltimore, MD: Centers for Medicare & Medicaid Services; 2022.  https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&ncaid=305. Accessed December 23, 2025."},{"issue":"2","key":"2131_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/CON.0000000000000313","volume":"22","author":"RC Petersen","year":"2016","unstructured":"Petersen RC. Mild cognitive impairment. Continuum. 2016;22(2):404\u201318. https:\/\/doi.org\/10.1212\/CON.0000000000000313.","journal-title":"Continuum"},{"issue":"1","key":"2131_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cger.2022.07.005","volume":"39","author":"RI Mehta","year":"2023","unstructured":"Mehta RI, Schneider JA. Neuropathology of the common forms of dementia. Clin Geriatr Med. 2023;39(1):91\u2013107. https:\/\/doi.org\/10.1016\/j.cger.2022.07.005.","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"2131_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","volume":"103","author":"A Atri","year":"2019","unstructured":"Atri A. The Alzheimer\u2019s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103(2):263\u201393. https:\/\/doi.org\/10.1016\/j.mcna.2018.10.009.","journal-title":"Med Clin North Am"},{"key":"2131_CR20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. Washington, DC: American Psychiatric Association; 2022. https:\/\/doi.org\/10.1176\/appi.books.9780890425787.","edition":"5th ed., text r"},{"key":"2131_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-024-00988-2","volume":"20","author":"RJ Jackson","year":"2024","unstructured":"Jackson RJ, Hyman BT, Serrano-Pozo A. Multifaceted roles of APOE in Alzheimer disease. Nat Rev Neurol. 2024;20:457\u201374. https:\/\/doi.org\/10.1038\/s41582-024-00988-2.","journal-title":"Nat Rev Neurol"},{"key":"2131_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid-related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784.","journal-title":"Front Neurosci"},{"issue":"8","key":"2131_CR23","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/brain\/awaf038","volume":"148","author":"H Liu","year":"2025","unstructured":"Liu H, et al. The landscape of autosomal dominant Alzheimer\u2019s disease: global data on mutation-specific phenotypes. Brain. 2025;148(8):2429\u201340. https:\/\/doi.org\/10.1093\/brain\/awaf038.","journal-title":"Brain"},{"issue":"2","key":"2131_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neuron.2010.10.013","volume":"68","author":"L Bertram","year":"2010","unstructured":"Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68(2):270\u201381. https:\/\/doi.org\/10.1016\/j.neuron.2010.10.013.","journal-title":"Neuron"},{"issue":"9","key":"2131_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J, et al. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(9):930\u201342. https:\/\/doi.org\/10.1016\/S1474-4422(21)00245-3.","journal-title":"Lancet Neurol"},{"key":"2131_CR26","unstructured":"U.S. Congress. National Alzheimer\u2019s Project Act. Pub L No. 111\u2013375, 124 Stat 4100 (2011). https:\/\/www.congress.gov\/111\/plaws\/publ375\/PLAW-111publ375.pdf.\u00a0Accessed 23 Sept 2025."},{"key":"2131_CR27","unstructured":"U.S. Congress. NAPA Reauthorization Act. Pub L No. 118\u201392, 138 Stat 1562 (2024). https:\/\/www.congress.gov\/118\/plaws\/publ92\/PLAW-118publ92.pdf.\u00a0Accessed 23 Sept 2025."},{"issue":"1","key":"2131_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"issue":"10510","key":"2131_CR29","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","volume":"406","author":"GB Frisoni","year":"2025","unstructured":"Frisoni GB, Hansson O, Nichols E, et al. New landscape of the diagnosis of Alzheimer\u2019s disease. Lancet. 2025;406(10510):1389\u2013407. https:\/\/doi.org\/10.1016\/S0140-6736(25)01294-2.","journal-title":"Lancet"},{"issue":"2","key":"2131_CR30","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","volume":"66","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging workgroup. J Nucl Med. 2025;66(2):S5\u201331. https:\/\/doi.org\/10.2967\/jnumed.124.268756.","journal-title":"J Nucl Med"},{"issue":"6","key":"2131_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2131_CR32","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20(9):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2131_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.neurobiolaging.2009.04.002","volume":"30","author":"JL Price","year":"2009","unstructured":"Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026\u201336. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.04.002.","journal-title":"Neurobiol Aging"},{"key":"2131_CR34","volume-title":"National Plan to Address Alzheimer\u2019s Disease: 2024 Update","author":"U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation","year":"2024","unstructured":"U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. National Plan to Address Alzheimer\u2019s Disease: 2024 Update. Washington, DC: Office of the Assistant Secretary for Planning and Evaluation; 2024."},{"issue":"12","key":"2131_CR35","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/jamaneurol.2023.3664","volume":"80","author":"RC Petersen","year":"2023","unstructured":"Petersen RC, Weintraub S, Sabbagh M, et al. A new framework for dementia nomenclature. JAMA Neurol. 2023;80(12):1364\u201370. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3664.","journal-title":"JAMA Neurol"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02131-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02131-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02131-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:01:16Z","timestamp":1783807276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02131-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02131-z","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}